Edwards Lifesciences Reports 9% Sales Growth in Q4 2024 with Earnings Beat

Details

The company achieved an earnings per share (EPS) of $0.58, beating the consensus EPS estimate. This growth was driven by strength across all product groups, with TAVR sales increasing by 6% and TMTT sales surging by 88%. The company also presented results from two significant FDA clinical trials, EARLY TAVR and TRISCEND II. Edwards Lifesciences expects to continue its growth trajectory in 2025 with an anticipated constant currency sales growth of 8% to 10%. The company is also optimistic about the potential of expanding its structural heart therapies portfolio.

Items reported

Exhibits (1)

About Edwards Lifesciences Corporation

Edwards Lifesciences Corporation is a leading healthcare company primarily known for its innovative medical devices focused on cardiovascular conditions. The firm's primary function revolves around the development and commercialization of heart valve products and hemodynamic monitoring systems, aimed at enhancing the life quality of patients suffering from cardiovascular diseases. Edwards Lifesciences plays a crucial role in the healthcare sector, particularly impacting the cardiology and surgical fields. Notable for its pioneering work in heart valve therapies, the corporation is at the forefront of transcatheter aortic valve replacement (TAVR) technology, a minimally invasive procedure that offers a significant alternative to traditional open-heart surgeries. Edwards Lifesciences collaborates closely with healthcare professionals to ensure its products address critical medical needs globally. Headquartered in Irvine, California, Edwards Lifesciences operates in a highly competitive and rapidly advancing market, where technological innovation and patient outcomes are pivotal. Its contributions continue to set standards within the medical device industry, reinforcing its market significance by addressing demands for effective cardiovascular care solutions worldwide.